

10686 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

26. Hayes, C. J., W. M. Gersong, W. B. Smith and V. P. Butler, "Serum Digoxin Studies in Infants and Children," Bulletin of New York Academy of Science, 47:1226, 1971.
27. White, R. J., D. A. Chamberlain, M. Howard and J. W. Smith, "Plasma Concentrations of Digoxin after Oral Administration in the Fasting and Postprandial State," British Medical Journal, p. 380, Feb. 13, 1971.
28. Bertler, A. and A. Redfors, "Plasma Digoxin Concentration," The Lancet, p. 50, July 3, 1971.
29. Fogelman, A. M., S. Finkelstein, J. T. LaMont, E. Rado and M. Pearce, "Fallibility of Plasma-Digoxin in Differentiating Toxic from Non-toxic Patients," The Lancet, p. 727, Oct. 2, 1971.
30. Chamberlain, D., A. Redfors, A. Bertler, J. Colbart and R. White, "The Value of Plasma-Digoxin Assay," The Lancet, p. 934, Oct. 23, 1971.
31. Evered, D. C., "The Value of Plasma-Digoxin Assay," The Lancet, p. 981, Oct. 30, 1971.
32. Smith, T. W., "The Clinical Use of Serum Cardiac Glycoside Concentration Measurements," The American Heart Journal, 83, No. 6:833-837, 1971.
33. Lindenbaum, J., M. H. Mellow, M. O. Blackstone and V. P. Butler, Jr., "Variation in Biologic Availability of Digoxin from Four Preparations," The New England Journal of Medicine, 285:1344-1347, 1971.